DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...
IVDs are essential for disease detection, personalized treatment, and public health, driving growth in the global diagnostics ...
DCN Dx, a specialist in diagnostics development, manufacturing, regulatory consulting, and clinical research, today announced the launch of a new prospective biospecimen collections offering, ...
This article is the third in Microbiologics’ series on Optimal QC in the Clinical Laboratory. Previously, in this series we highlighted the importance of external and third-party quality control ...
GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic ...
As the diagnostic industry evolves under new regulations and advancing technologies, outsourcing production has become vital to maintain innovation and speed. Yet, identifying the right manufacturing ...
On April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs).[1] The rule explicitly categorizes in vitro diagnostic products (IVDs) intended for clinical use ...
The new partnership combines QIAGEN’s QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX’s expertise in multiplex assay development. The aim is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback